Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03928314
Title Study of ORIC-101 in Combination With Anticancer Therapy
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors Oric Pharmaceuticals
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Stanford Cancer Institute Palo Alto California 94304 United States Details
UCSF Helen Diller Family Comprehensive Cancer Center San Francisco California 94115 United States Details
University of Colorado - PPDS Aurora Colorado 80045 United States Details
Florida Cancer Specialists & Research Institute Lake Mary Florida 32746 United States Details
Florida Cancer Specialists & Research Institute Sarasota Florida 34232 United States Details
Oregon Health & Science University Portland Oregon 97239 United States Details
Tennessee Oncology NASH - SCRI - PPDS Nashville Tennessee 37203 United States Details
Mary Crowley Cancer Research Centers - Medical City Dallas Texas 75231 United States Details
University of Texas MD Anderson Cancer Center Houston Texas 77030 United States Details
NEXT Oncology San Antonio Texas 78229 United States Details
University of Utah - Huntsman Cancer Institute - PPDS Salt Lake City Utah 84112 United States Details
Virginia Cancer Specialists, PC Fairfax Virginia 22031 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field